Oral division
Orforglipron (Foundayo)
BCompetitive
Eli Lilly · approved
vs
Injectable division
Tirzepatide (Zepbound)
Class-leadingA
Eli Lilly · approved
9%
Efficacy
9 pts more · 18%
Notable (+7.6)
Tolerability
gentler · Mild (+3.6)
Oral pill
Route
Subcutaneous injection
None
Food / water rule
None
Room temperature
Storage
Refrigerated (room temperature up to 21 days)
The trade: Different divisions, so this is the trade, not a verdict. Tirzepatide loses about 9 more points of body weight. Orforglipron adds convenience: a daily pill instead of a once weekly injection, no cold chain, supply that scales. If maximum loss matters most and an injection is acceptable, Tirzepatide; if avoiding the needle matters more, Orforglipron.
Standalone, this page carries its own key: Efficacy = % body weight lost vs placebo, on the conservative estimand that counts everyone. Tolerability = AE-discontinuation over placebo (Mild 1 to 5 · Notable 5 to 10 · Heavy over 10 points). Different divisions, so efficacy is shown as raw magnitude, not a verdict. The side marked leads or gentler wins that axis.
Orforglipron verdict · Tirzepatide verdict · Is the pill as good as the shot? · How this is scored